http://bit.ly/1zfNXza NEW YORK – The World Health Organization will host a closed-door conference in Geneva with some 100 health-care experts from around the world to explore the alternative medical treatments and experimental drugs available to combat Ebola. The WHO hopes the conference, Sept. 4-5, will lead to the approval of one or more treatments to combat the current Ebola outbreak in Africa. WHO spokeswoman Fadela Chaib in Geneva explained to WND in an exclusive telephone interview that while journalists will be excluded from the meeting, the WHO will conduct a media advisory at the conclusion to allow journalists to ask questions. The WHO decision to explore experimental Ebola drugs and treatments appears to have been prompted in part by a widely reported offer made Monday by the Japanese company Toyama Chemical, a pharmaceutical subsidiary of the photo giant Fujifilm. The Japanese company will deliver to the WHO at no cost a quantity of the experimental drug Favipiravir, originally known as “T-705.” The drug is marketed by Toyama Chemical under the trade name “Avigan.” The company will supply enough doses for 20,000 people in an attempt to control the Ebola outbreak affecting West Africa. Yoshihide Suga, a spokesman for the Japanese cabinet, affirmed Toyama Chemical is ready to ship the drug at any time to West Africa upon the approval of the WHO. He said Japan’s health ministry approved in March the use of Avigan against influenza. Fujifilm is in talks with the U.S. Food and Drug Administration through a U.S. partner, Boston-based MediVector, to prepare for clinical testing of the drug in the United States, the Associated Press reported Monday. Read more at http://bit.ly/VQRS6v
WHO Calls 'Emergency Meeting', Setting the Stage to Ok 'Experimental' Ebola Drugs!
http://bit.ly/1zfNXza NEW YORK – The World Health Organization will host a closed-door conference in Geneva with some 100 health-care experts from around the world to explore the alternative medical treatments and experimental drugs available to combat Ebola. The WHO hopes the conference, Sept. 4-5, will lead to the approval of one or more treatments to combat the current Ebola outbreak in Africa. WHO spokeswoman Fadela Chaib in Geneva explained to WND in an exclusive telephone interview that while journalists will be excluded from the meeting, the WHO will conduct a media advisory at the conclusion to allow journalists to ask questions. The WHO decision to explore experimental Ebola drugs and treatments appears to have been prompted in part by a widely reported offer made Monday by the Japanese company Toyama Chemical, a pharmaceutical subsidiary of the photo giant Fujifilm. The Japanese company will deliver to the WHO at no cost a quantity of the experimental drug Favipiravir, originally known as “T-705.” The drug is marketed by Toyama Chemical under the trade name “Avigan.” The company will supply enough doses for 20,000 people in an attempt to control the Ebola outbreak affecting West Africa. Yoshihide Suga, a spokesman for the Japanese cabinet, affirmed Toyama Chemical is ready to ship the drug at any time to West Africa upon the approval of the WHO. He said Japan’s health ministry approved in March the use of Avigan against influenza. Fujifilm is in talks with the U.S. Food and Drug Administration through a U.S. partner, Boston-based MediVector, to prepare for clinical testing of the drug in the United States, the Associated Press reported Monday. Read more at http://bit.ly/VQRS6v
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment